An opiate screen can miss fentanyl when fentanyl is outside the assay’s target scope. The 2016 New Haven outbreak provides a concrete example: the urine immunoassay used in the investigation could not detect fentanyl or its analogs, while later mass-spectrometric testing and medical examiner testing identified fentanyl exposure. That is a limitation of the particular screening approach, not evidence that every current opioid assay has the same scope.
Twelve cases did not mean twelve identical toxicology workups
Tomassoni and colleagues described 12 people brought to Yale New Haven Hospital during an outbreak on June 23, 2016, after a white powder had been sold as cocaine. The route was unknown but presumed to be intranasal in most cases. Nine patients were admitted; four received intensive care. Two arrived dead, and another died three days later in hospital.
The case definition combined clinical opioid toxicity and response to naloxone with either laboratory evidence of fentanyl or its metabolites, or a direct association with a laboratory-confirmed exposure. This was an outbreak investigation, not a blinded diagnostic-accuracy study of an opiate immunoassay.
Qualitative urine immunoassays were performed in nine patients. The authors explicitly stated that those tests could not detect fentanyl and its analogs. Eight of the nine urine screens were cocaine-positive. These cocaine findings were a separate part of the panel and did not show that fentanyl had been tested and excluded.
What later testing added
Serum and urine were subsequently investigated at the University of California, San Francisco using liquid chromatography–high-resolution mass spectrometry. The report described screening for 215 common drugs and metabolites, followed by additional searching for 7,038 novel drugs and metabolites. Fentanyl, cocaine, benzoylecgonine and levamisole were quantified; additional compounds were reported qualitatively.
Nine hospitalized patients had fentanyl detected in blood collected during hospitalization. One associated patient left before the outbreak was fully recognized and did not receive confirmatory toxicology testing. The medical examiner separately tested postmortem specimens from the two people who died before arrival. These different pathways should remain visible when reading the total of 12 cases.
The article did not provide a complete matrix-specific validation dataset for the outbreak measurements, including all detection limits, quantitation limits and uncertainty estimates. A large searchable library is not equivalent to demonstrated uniform sensitivity for every listed compound.
Hospital serum and postmortem specimens answer different questions
Fentanyl concentrations in the hospitalized group were 0.5–9.5 ng/mL. The two deaths before arrival had reported postmortem concentrations of 11 and 13 ng/mL. The postmortem specimens were identified in a table footnote as medical examiner specimens; the report did not establish their anatomical collection sites or precise death-to-collection intervals.
These values are not paired before-and-after measurements from the same people. They cannot quantify a redistribution factor or establish a concentration separating survival from death. The patient with the 9.5-ng/mL hospital result later died, further emphasizing the importance of when a specimen was obtained and what subsequent outcome is being compared.
Norfentanyl was reported in the serum of nine patients but not in the two early deaths’ postmortem testing. The authors proposed rapid death before substantial metabolism as an explanation. They did not validate absent norfentanyl as a precise exposure clock. Sampling, analytical scope and reporting limits must be considered before turning a metabolite pattern into a timing conclusion.
Evidence about the powder was a separate specimen
A 32-mg sample of illicit material collected by law enforcement contained 6.6% ±0.8% fentanyl by weight, with trace cocaine and an inert adulterant. This supported the outbreak investigation, but it did not measure the amount consumed by any patient. Product composition, a blood concentration and the dose taken are different measurements.
The two postmortem investigations identified fentanyl as a cause of death in their case context. That conclusion was not derived solely from the absence of a positive opiate screen. Clinical findings, circumstances and targeted toxicological evidence supplied different pieces of the investigation.
What to establish when reviewing a negative result
The central question is whether the actual assay could detect the substance at issue in the submitted matrix and at its reporting threshold. The label “opiates” alone does not answer it. A report should distinguish the initial class screen, later analyte identification, quantitative results and postmortem interpretation.
Our article on negative autopsy drug screens discusses broader coverage limitations. For the separate problem of comparing living and deceased groups, see postmortem and antemortem fentanyl comparisons.
Primary source
Tomassoni AJ, Hawk KF, Jubanyik K, et al. Multiple Fentanyl Overdoses—New Haven, Connecticut, June 23, 2016. MMWR Morbidity and Mortality Weekly Report. 2017;66:107–111. https://doi.org/10.15585/mm6604a4.
Leave a Reply